Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442398 | 0.79 | KMT2A (0.40) | KMT2AMEN1TDP1POLBALDH1A1 | |
| SCHEMBL3579254 | 0.70 | PDE5A (0.46) | KMT2AMEN1POLBALDH1A1MAPK1 | |
| SCHEMBL6450443 | 0.69 | PDE5A (0.49) | KMT2AMEN1POLBALDH1A1KDM4E | |
| SCHEMBL6447286 | 0.68 | MEN1 (0.39) | KMT2AMEN1TDP1POLBALDH1A1 | |
| SCHEMBL6443470 | 0.67 | MAPT (0.43) | KMT2AMEN1ALDH1A1MAPK1KDM4E | |
| SCHEMBL6446798 | 0.67 | PDE5A (0.39) | KMT2AMEN1ALDH1A1MAPK1GRM4 | |
| Nitric Acid SCHEMBL7835145 | 0.66 | MAPT (0.40) | KMT2AMEN1ALDH1A1MAPK1KDM4E | |
| SCHEMBL7002706 | 0.66 | MAPT (0.42) | KMT2AMEN1POLBALDH1A1MAPK1 | |
| SCHEMBL6442334 | 0.65 | MAPT (0.48) | KMT2AMEN1POLBALDH1A1KDM4E | |
| Nitric Acid SCHEMBL7392245 | 0.65 | MAPT (0.46) | KMT2AMEN1POLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | KMT2A 4533/4885MEN1 4096/4885TDP1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.